Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer.
作者信息
Nicolazzo Chiara, Belardinilli Francesca, Caponnetto Salvatore, Gradilone Angela, Cortesi Enrico, Giannini Giuseppe, Gazzaniga Paola
机构信息
Liquid Biopsy Unit, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
出版信息
Front Oncol. 2019 Dec 17;9:1414. doi: 10.3389/fonc.2019.01414. eCollection 2019.
Abstract
摘要
相似文献
1
Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer.为何血浆循环肿瘤DNA中RAS突变清除的治疗影响值得在转移性结直肠癌中进一步探索。
Front Oncol. 2019 Dec 17;9:1414. doi: 10.3389/fonc.2019.01414. eCollection 2019.
2
Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients.循环甲基化DNA用于监测转移性结直肠癌患者血浆中RAS突变清除的动态变化
Cancers (Basel). 2020 Dec 4;12(12):3633. doi: 10.3390/cancers12123633.
3
Plasma ctDNA RAS status selects patients for anti-EGFR treatment rechallenge in metastatic colorectal cancer: a meta-analysis.血浆 ctDNA RAS 状态可选择转移性结直肠癌患者进行抗 EGFR 治疗再挑战：一项荟萃分析。
Exp Oncol. 2021 Sep;43(3):252-256. doi: 10.32471/exp-oncology.2312-8852.vol-43-no-3.16592.
4
Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.在治疗压力下，RAS突变的血浆清除在转移性结直肠癌中是一种罕见事件。
Int J Cancer. 2020 Aug 15;147(4):1185-1189. doi: 10.1002/ijc.32657. Epub 2019 Oct 12.
5
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.基于血液和肿瘤检测的RAS突变一致性以指导转移性结直肠癌的抗表皮生长因子受体治疗
Ann Oncol. 2017 Jun 1;28(6):1294-1301. doi: 10.1093/annonc/mdx112.
6
A Trial Protocol of Precision Medicine for Patients with RAS Wild Metastatic Colorectal Cancer Using Liquid Biopsy (RAS-liquid Study): A Prospective, Multicenter Observational Study.一项使用液体活检对RAS野生型转移性结直肠癌患者进行精准医学的试验方案（RAS液体研究）：一项前瞻性、多中心观察性研究。
J Anus Rectum Colon. 2022 Jan 28;6(1):52-57. doi: 10.23922/jarc.2021-042. eCollection 2022.
7
Genomic landscape and survival analysis of ctDNA "neo- wild-type" patients with originally mutant metastatic colorectal cancer.原发性突变转移性结直肠癌ctDNA“新野生型”患者的基因组图谱与生存分析
Front Oncol. 2023 Mar 29;13:1160673. doi: 10.3389/fonc.2023.1160673. eCollection 2023.
8
Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.血浆循环肿瘤DNA RAS突变分析在转移性结直肠癌患者诊断及治疗监测中的应用
Ann Oncol. 2017 Jun 1;28(6):1325-1332. doi: 10.1093/annonc/mdx125.
9
Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.液体活检 RAS/BRAF 循环肿瘤 DNA 分析用于转移性结直肠癌患者的临床实施的诊断策略。
J Mol Diagn. 2020 Dec;22(12):1430-1437. doi: 10.1016/j.jmoldx.2020.09.002. Epub 2020 Sep 19.
10
Clinical Validation of Plasma-Based Genotyping for and V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy.基于血浆的种系基因检测在转移性结直肠癌和 V600E 突变中的临床验证：SCRUM-Japan GOZILA 子研究。
JCO Precis Oncol. 2023 Jun;7:e2200688. doi: 10.1200/PO.22.00688.
引用本文的文献
1
Neo-RAS Wild Type or RAS Conversion in Metastatic Colorectal Cancer: A Comprehensive Narrative Review.转移性结直肠癌中的新RAS野生型或RAS转化：一篇全面的叙述性综述。
Cancers (Basel). 2024 Nov 22;16(23):3923. doi: 10.3390/cancers16233923.
2
Kinetic Profiling of Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of Mutations in Neo--Wildtype Metastatic Colorectal Cancer Is Transient.在加拿大癌症临床试验组 CO.26 试验中，利用循环肿瘤 DNA 进行的突变动力学分析表明，新野生型转移性结直肠癌中突变的丢失是暂时的。
JCO Precis Oncol. 2024 Aug;8:e2400031. doi: 10.1200/PO.24.00031.
3
Genomic landscape and survival analysis of ctDNA "neo- wild-type" patients with originally mutant metastatic colorectal cancer.原发性突变转移性结直肠癌ctDNA“新野生型”患者的基因组图谱与生存分析
Front Oncol. 2023 Mar 29;13:1160673. doi: 10.3389/fonc.2023.1160673. eCollection 2023.
4
Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study.贝伐单抗治疗的转移性结直肠癌患者中的突变转换：一项基于液体活检的研究。
Cancers (Basel). 2022 Feb 4;14(3):802. doi: 10.3390/cancers14030802.
5
Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments.两种基于血液的基因分型检测在一线治疗失败的非小细胞肺癌患者中检测KRAS G12C突变的比较
Diagnostics (Basel). 2021 Nov 25;11(12):2196. doi: 10.3390/diagnostics11122196.
本文引用的文献
1
EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment.表皮生长因子受体抑制剂作为一名转移性结直肠癌突变患者的二线治疗：利用循环肿瘤DNA实现个性化治疗
JCO Precis Oncol. 2018 Nov;2:1-6. doi: 10.1200/PO.17.00277.
2
Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality.结直肠癌中的循环肿瘤DNA分析：从梦想走向现实
JCO Precis Oncol. 2019 Dec;3:1-14. doi: 10.1200/PO.18.00397.
3
Correlation Between Tumor-Specific Mutated and Methylated DNA in Colorectal Cancer.结直肠癌中肿瘤特异性突变DNA与甲基化DNA的相关性
JCO Precis Oncol. 2019 Dec;3:1-8. doi: 10.1200/PO.18.00162.
4
Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.在治疗压力下，RAS突变的血浆清除在转移性结直肠癌中是一种罕见事件。
Int J Cancer. 2020 Aug 15;147(4):1185-1189. doi: 10.1002/ijc.32657. Epub 2019 Oct 12.
5
How liquid biopsies can change clinical practice in oncology.液体活检如何改变肿瘤学的临床实践。
Ann Oncol. 2019 Oct 1;30(10):1580-1590. doi: 10.1093/annonc/mdz227.
6
Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.对比液活检样本中 Idylla 平台与 OncoBEAM RAS CRC 检测试剂盒检测 KRAS 基因突变的临床灵敏度。
Sci Rep. 2019 Jun 20;9(1):8976. doi: 10.1038/s41598-019-45616-y.
7
Roles of Methylated DNA Biomarkers in Patients with Colorectal Cancer.甲基化 DNA 生物标志物在结直肠癌患者中的作用。
Dis Markers. 2019 Mar 3;2019:2673543. doi: 10.1155/2019/2673543. eCollection 2019.
8
Systemic treatment for metastatic colorectal cancer in the era of precision medicine.精准医学时代转移性结直肠癌的全身治疗
J Surg Oncol. 2019 Apr;119(5):564-582. doi: 10.1002/jso.25421. Epub 2019 Feb 25.
9
Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer.血浆中RAS突变克隆的短暂消失：EGFR抑制剂在RAS突变型转移性结直肠癌中的一种违反直觉的临床应用
Cancers (Basel). 2019 Jan 4;11(1):42. doi: 10.3390/cancers11010042.
10
Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer.转移性结直肠癌的分子亚型与治疗决策的演变
Am Soc Clin Oncol Educ Book. 2018 May 23;38:231-238. doi: 10.1200/EDBK_200929.
Zotero 插件